Protagonist Therapeutics, Inc (NASDAQ: PTGX)

Protagonist Therapeutics, Inc. is an integrated discovery and development company focused on creating peptide based therapeutics for inflammatory and immunologic disorders hematologic conditions and metabolic diseases. The company uses a proprietary technology platform to design oral and injectable peptides that target validated biological pathways. Its pipeline includes programs in inflammation and immunology hematology and obesity and metabolic disease.

Protagonist Therapeutics generates revenue primarily through collaboration agreements with larger pharmaceutical partners. Under these agreements the company receives upfront payments milestone payments and is eligible to receive royalties on future product sales. Currently the company has no commercial product sales and relies on payments from its partnerships with Janssen Biotech and Takeda Pharmaceuticals to fund its research and development activities.

Within the biotechnology industry Protagonist Therapeutics positions itself as a developer of oral peptide therapies that address limitations of current injectable biologics. In the inflammation and immunology space its candidates compete with established agents such as Cosentyx Taltz Siliq Tremfya Skyrizi and various JAK inhibitors. In hematology its rusfertide candidate faces competition from hydroxyurea interferons and JAK inhibitors like ruxolitinib. In the obesity market the company’s dual and triple agonist peptides compete with approved incretin based therapies such as Wegovy and Zepbound and emerging molecules like retatrutide. The company’s competitive advantages stem from its proprietary peptide platform which enables oral delivery of molecules that traditionally require injection and its focus on targets with strong biological validation.

The company’s customers are the patients who will eventually use its approved therapies and the healthcare providers who prescribe them. Through its collaboration agreements Protagonist Therapeutics works closely with Janssen Biotech and Takeda Pharmaceuticals which oversee later stage development manufacturing and commercialization of the drug candidates. These partners represent the primary customers for the company’s early stage research and development output.